Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 838916, 8 pages
http://dx.doi.org/10.1100/2012/838916
Review Article

The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond

Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA

Received 7 July 2011; Accepted 14 October 2011

Academic Editor: Ludger Hengst

Copyright © 2012 Fotini M. Kouri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Kleihues, D. N. Louis, B. W. Scheithauer et al., “The WHO classification of tumors of the nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 3, pp. 215–225, 2002. View at Google Scholar
  2. P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” The New England Journal of Medicine, vol. 359, no. 5, pp. 492–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson, “Mechanisms of disease: cell death,” The New England Journal of Medicine, vol. 361, no. 16, pp. 1570–1583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. A. Andrews, S. Xi, R. G. Pomerantz et al., “Mutation of P53 in head and neck squamous cell carcinoma correlates with BCL-2 expression and increased susceptibility to cisplatin-induced apoptosis,” Head and Neck, vol. 26, no. 10, pp. 870–877, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Ikegaki, M. Katsumata, J. Minna, and Y. Tsujimoto, “Expression of bcl-2 in small cell lung carcinoma cells,” Cancer Research, vol. 54, no. 1, pp. 6–8, 1994. View at Google Scholar · View at Scopus
  6. O. Monni, H. Joensuu, K. Franssila, J. Klefstrom, K. Alitalo, and S. Knuutila, “BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma,” Blood, vol. 90, no. 3, pp. 1168–1174, 1997. View at Google Scholar · View at Scopus
  7. M. E. Peter and P. H. Krammer, “The CD95(APO-1/Fas) DISC and beyond,” Cell Death and Differentiation, vol. 10, no. 1, pp. 26–35, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Gavathiotis, D. E. Reyna, M. L. Davis, G. H. Bird, and L. D. Walensky, “BH3-triggered structural reorganization drives the activation of proapoptotic BAX,” Molecular Cell, vol. 40, no. 3, pp. 481–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997. View at Google Scholar · View at Scopus
  11. P. G. Ekert and D. L. Vaux, “The mitochondrial death squad: hardened killers or innocent bystanders?” Current Opinion in Cell Biology, vol. 17, no. 6, pp. 626–630, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Strik, M. Deininger, J. Streffer et al., “BCL-1 family protein expression in initial and recurrent glioblastomas: modulation by chemotherapy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 67, no. 6, pp. 763–768, 1999. View at Google Scholar
  13. T. Doucette, Y. Yang, W. Zhang et al., “Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma,” International Journal of Cancer, vol. 129, no. 9, pp. 2093–2103, 2011. View at Publisher · View at Google Scholar
  14. C. Fels, C. Schäfer, B. Hüppe et al., “Bcl-2 expression in higher-grade human glioma: a clinical and experimental study,” Journal of Neuro-Oncology, vol. 48, no. 3, pp. 207–216, 2000. View at Publisher · View at Google Scholar
  15. F. E. McDonald, J. W. Ironside, A. Gregor et al., “The prognostic influence of bcl-2 in malignant glioma,” British Journal of Cancer, vol. 86, no. 12, pp. 1899–1904, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Krajewski, M. Krajewska, J. Ehrmann et al., “Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin,” American Journal of Pathology, vol. 150, no. 3, pp. 805–814, 1997. View at Google Scholar · View at Scopus
  17. D. C. S. Huang, L. A. O'Reilly, A. Strasser, and S. Cory, “The anti-apoptosis function of: Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry,” EMBO Journal, vol. 16, no. 15, pp. 4628–4638, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Lin, S. K. Kolluri, F. Lin et al., “Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3,” Cell, vol. 116, no. 4, pp. 527–540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Lewis, G. A. Oyler, K. Ueno et al., “Inhibition of virus-induced neuronal apoptosis by Bax,” Nature Medicine, vol. 5, no. 7, pp. 832–835, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Fannjiang, C. H. Kim, R. L. Huganir et al., “BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development,” Developmental Cell, vol. 4, no. 4, pp. 575–585, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Kamer, R. Sarig, Y. Zaltsman et al., “Proapoptotic BID is an ATM effector in the DNA-damage response,” Cell, vol. 122, no. 4, pp. 593–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. S. Zinkel, K. E. Hurov, C. Ong, F. M. Abtahi, A. Gross, and S. J. Korsmeyer, “A role for proapoptotic BID in the DNA-damage response,” Cell, vol. 122, no. 4, pp. 579–591, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Nagane, A. Levitzki, A. Gazit, W. K. Cavenee, and H. J. S. Huang, “Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 10, pp. 5724–5729, 1998. View at Google Scholar · View at Scopus
  24. H. Zhu, X. Cao, F. Ali-Osman, S. Keir, and H. W. Lo, “EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity,” Cancer Letters, vol. 294, no. 1, pp. 101–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Konishi, F. Yi, X. Chen, H. Vo, D. P. Carbone, and T. P. Dang, “Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim,” Oncogene, vol. 29, no. 4, pp. 589–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Li, S. Zhou, L. Zhang et al., “BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer,” Medical Oncology, vol. 28, pp. 572–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Deng, T. Shimamura, S. Perera et al., “Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion,” Cancer Research, vol. 67, no. 24, pp. 11867–11875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Cragg, J. Kuroda, H. Puthalakath, D. C. S. Huang, and A. Strasser, “Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics,” PLoS Medicine, vol. 4, no. 10, pp. 1681–1690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. B. Costa, B. Halmos, A. Kumar et al., “BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations,” PLoS Medicine, vol. 4, no. 10, pp. 1669–1680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. R. Quadros, S. Connelly, C. Kari, M. T. Abrams, E. Wickstrom, and U. Rodeck, “EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-δ activities,” Cancer Biology and Therapy, vol. 5, no. 5, pp. 498–504, 2006. View at Google Scholar · View at Scopus
  31. A. H. Stegh, H. Kim, R. M. Bachoo et al., “Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma,” Genes and Development, vol. 21, no. 1, pp. 98–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Scorilas, L. Kyriakopoulou, G. M. Yousef, L. K. Ashworth, A. Kwamie, and E. P. Diamandis, “Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family,” Genomics, vol. 72, no. 2, pp. 217–221, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. H. Stegh, S. Kesari, J. E. Mahoney et al., “Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 31, pp. 10703–10708, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. H. Stegh, L. Chin, D. N. Louis, and R. A. DePinho, “What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator,” Cell Cycle, vol. 7, no. 18, pp. 2833–2839, 2008. View at Google Scholar · View at Scopus
  35. W. X. Zong and C. B. Thompson, “Necrotic death as a cell fate,” Genes and Development, vol. 20, no. 1, pp. 1–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. A. H. Stegh, C. Brennan, J. A. Mahoney et al., “Glioma oncoprotein Bc12L12 inhibits the p53 tumor suppressor,” Genes and Development, vol. 24, no. 19, pp. 2194–2204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. H. Stegh and R. A. DePinho, “Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma,” Cell Cycle, vol. 10, no. 1, pp. 33–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. S. Phillips, S. Kharbanda, R. Chen et al., “Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis,” Cancer Cell, vol. 9, no. 3, pp. 157–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. K. E. Tagscherer, A. Fassl, B. Campos et al., “Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins,” Oncogene, vol. 27, no. 52, pp. 6646–6656, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Manero, F. Gautier, T. Gallenne et al., “The small organic compound HA14-1 prevents Bcl-2 interaction with bax to sensitize malignant glioma cells to induction of cell death,” Cancer Research, vol. 66, no. 5, pp. 2757–2764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Dodou, R. J. Anderson, D. A. P. Small, and P. W. Groundwater, “Investigations of gossypol: past and present developments,” Expert Opinion on Investigational Drugs, vol. 14, no. 11, pp. 1419–1434, 2005. View at Google Scholar
  43. P. Bushunow, M. M. Reidenberg, J. Wasenko et al., “Gossypol treatment of recurrent adult malignant gliomas,” Journal of Neuro-Oncology, vol. 43, no. 1, pp. 79–86, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Fischer and K. Schulze-Osthoff, “New approaches and therapeutics targeting apoptosis in disease,” Pharmacological Reviews, vol. 57, no. 2, pp. 187–215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Horiguchi, T. Asano, K. Kuroda et al., “STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma,” British Journal of Cancer, vol. 102, no. 11, pp. 1592–1599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Iwamaru, S. Szymanski, E. Iwado et al., “A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo,” Oncogene, vol. 26, no. 17, pp. 2435–2444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Y. Kong, A. S. Wu, T. Doucette et al., “Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses,” Clinical Cancer Research, vol. 16, no. 23, pp. 5722–5733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. L. D. Walensky, K. Pitter, J. Morash et al., “A stapled BID BH3 helix directly binds and activates BAX,” Molecular Cell, vol. 24, no. 2, pp. 199–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Xu, X. Liao, and C. Wong, “Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG,” International Journal of Cancer, vol. 126, no. 4, pp. 1029–1035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Shi, J. Chen, J. Yang, T. Pan, S. Zhang, and Z. Wang, “MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity,” Brain Research, vol. 1352, pp. 255–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. U. Naumann, F. Schmidt, W. Wick et al., “Adenoviral natural born killer gene therapy for malignant glioma,” Human Gene Therapy, vol. 14, no. 13, pp. 1235–1246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. M. A. Vogelbaum, J. X. Tong, R. Perugu, D. H. Gutmann, and K. M. Rich, “Overexpression of bax in human glioma cell lines,” Journal of Neurosurgery, vol. 91, no. 3, pp. 483–489, 1999. View at Google Scholar · View at Scopus
  54. J. R. Streffer, A. Rimner, J. Rieger, U. Naumann, H. P. Rodemann, and M. Weller, “BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells,” Journal of Neuro-Oncology, vol. 56, no. 1, pp. 43–49, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. P. N. Kelly and A. Strasser, “The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy,” Cell Death and Differentiation, vol. 18, no. 9, pp. 1414–1424, 2011. View at Publisher · View at Google Scholar
  56. X. Lin, S. Morgan-Lappe, X. Huang et al., ““Seed” analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737,” Oncogene, vol. 26, no. 27, pp. 3972–3979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. C. J. Zhu, Y. B. Li, and M. C. Wong, “Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells,” Journal of Neuroscience Research, vol. 74, no. 1, pp. 60–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Agrawal, D. H. Min, N. Singh et al., “Functional delivery of siRNA in mice using dendriworms,” ACS Nano, vol. 3, no. 9, pp. 2495–2504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Ding, S. Inoue, A. V. Ljubimov et al., “Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 42, pp. 18143–18148, 2010, Corrected in: Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Das, M. Srikanth, and J. A. Kessler, “Cancer stem cells and glioma,” Nature Clinical Practice Neurology, vol. 4, no. 8, pp. 427–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Sheng, L. Li, L. J. Zhu et al., “A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications,” Nature Medicine, vol. 16, no. 6, pp. 671–677, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. N. N. Danial, A. Gimenez-Cassina, and D. Tondera, “Homeostatic functions of BCL-2 proteins beyond apoptosis,” Advances in Experimental Medicine and Biology, vol. 687, pp. 1–32, 2010. View at Google Scholar · View at Scopus